Our RESETTM clinical trials with CABA-201 (investigational CD19-CAR T cell therapy) in lupus, myositis, systemic sclerosis, myasthenia gravis, and pemphigus vulgaris are now recruiting.
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 05/03/21 | 8-K | Current report filing |
|
52 | |
| 04/21/21 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
|
4 | |
| 04/21/21 | DEF 14A | Definitive proxy statements |
|
42 | |
| 04/06/21 | 8-K | Current report filing |
|
33 | |
| 03/16/21 | S-8 | Initial registration statement for securities to be offered to employees pursuant to employee benefit plans |
|
8 | |
| 03/16/21 | 10-K | Annual report pursuant to Section 13 and 15(d) |
|
   |
179 |
| 03/16/21 | 8-K | Current report filing |
|
8 | |
| 03/02/21 | 4 | Statement of changes in beneficial ownership of securities |
|
2 | |
| 03/02/21 | 4 | Statement of changes in beneficial ownership of securities |
|
2 | |
| 03/02/21 | 4 | Statement of changes in beneficial ownership of securities |
|
2 |
